The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor–stroma crosstalk
Open accessAbstract
Significance: Pancreatic ductal adenocarcinoma (PDA) is the third leading of cause of cancer death in the United States and is predicted to be the second one by 2030. The tumor microenvironment is a major source of soluble mediators that influence tumor progression and hinder the success of therapeutic strategies. Using a genetically engineered mouse model and human cell-based systems, we identify galectin-1 (Gal1) as a critical soluble factor capable of regulating tumor–stroma crosstalk promoting proliferation, angiogenesis, and modulation of inflammatory responses, resulting in enhanced tumor development and metastasis. Our data provide an integrated view of the role of Gal1 in the PDA microenvironment and reinforce the high therapeutic value of Gal1 inhibition in PDA treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621 · cited 1×
“Notwithstanding, recent genome-wide studies have identified molecular signatures (83) and unique neoantigen properties (84) that may be useful for stratifying PDA patients for immunotherapy.”
BackgroundÖzdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.005 · Cited by 2,681
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642
Hidalgo, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901557 · Cited by 2,570
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Initiative, A. P. C. G., Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M.-C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A.-M., et al. (2012) · Nature · doi:10.1038/nature11547 · Cited by 2,058
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
Initiative, A. P. C. G., Balachandran, V. P., Łuksza, M., Zhao, J. N., Makarov, V., Moral, J. A., Remark, R., Herbst, B., Askan, G., Bhanot, U., et al. (2017) · Nature · doi:10.1038/nature24462 · Cited by 1,191
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
Jacobetz, M. A., Chan, D. S., Neesse, A., Bapiro, T. E., Cook, N., Frese, K. K., Feig, C., Nakagawa, T., Caldwell, M. E., Zecchini, H. I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-302529 · Cited by 1,120
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J., Mollaee, M., Wagner, K.-U., Koduru, P., Yopp, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7744 · Cited by 1,115
Dynamics of the immune reaction to pancreatic cancer from inception to invasion
Clark, C. E., Hingorani, S. R., Mick, R., Combs, C., Tuveson, D. A., & Vonderheide, R. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0175 · Cited by 990 · cited 4×
“Importantly, mouse Kras-driven models recapitulate not only these two features of human PDA but also its profound immunosuppression (33) and tumor genetic heterogeneity (55–60).”
BackgroundInfluentialBayne, L. J., Beatty, G. L., Jhala, N., Clark, C. E., Rhim, A. D., Stanger, B. Z., & Vonderheide, R. H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.025 · Cited by 947 · cited 1×
“Data from murine PDA models have provided new mechanisms for PDA immunosuppression, showing that MDSCs can be recruited through Krasdriven paracrine secretion of GM-CSF by tumor cells (85, 86).”
BackgroundOncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
Collins, M. A., Bednar, F., Zhang, Y., Brisset, J.-C., Galbán, S., Galbán, C. J., Rakshit, S., Flannagan, K. S., Adsay, N. V., & Pasca di Magliano, M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59227 · Cited by 770 · cited 1×
“Another key hallmark of PDA is KRAS mutations, which are present in >90% of PDA patients (24) and are essential for tumor initiation and progression (53, 54).”
BackgroundOncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia
Pylayeva-Gupta, Y., Lee, K. E., Hajdu, C. H., Miller, G., & Bar-Sagi, D. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.024 · Cited by 721 · cited 1×
“Data from murine PDA models have provided new mechanisms for PDA immunosuppression, showing that MDSCs can be recruited through Krasdriven paracrine secretion of GM-CSF by tumor cells (85, 86).”
BackgroundToscano, M. A., Bianco, G. A., Ilarregui, J. M., Croci, D. O., Correale, J., Hernandez, J. D., Zwirner, N. W., Poirier, F., Riley, E. M., Baum, L. G., et al. (2007) · Nature Immunology · doi:10.1038/ni1482 · Cited by 653 · cited 2×
“This effect may be directly related to T cell dysfunction induced by Gal1, as this lectin impairs T cell viability and suppresses the synthesis of T cell-derived proinflammatory cytokines (45, 96), or may involve the repression of regulatory circuits mediated by MDSCs or tolerogenic dendritic cells, leading to subsequ…”
BackgroundSelf-citationGuerra, C., Collado, M., Navas, C., Schuhmacher, A. J., Hernández-Porras, I., Cañamero, M., Rodriguez-Justo, M., Serrano, M., & Barbacid, M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.05.011 · Cited by 516 · cited 5×
“In contrast, the Ela-Krasp53 mice used in this work faithfully recapitulate the full spectrum of pancreatic intraepithelial neoplasias that progress to human-like PDA tumors and, like PDA patients, develop liver metastases (28, 48), thus making this model an ideal system for testing novel molecular targets.”
BackgroundMethodInfluentialSelf-citationStromal response to Hedgehog signaling restrains pancreatic cancer progression
Lee, J. J., Perera, R. M., Wang, H., Wu, D.-C., Liu, X. S., Han, S., Fitamant, J., Jones, P. D., Ghanta, K. S., Kawano, S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411679111 · Cited by 502
Genetic progression in the pancreatic ducts
Hruban, R. H., Wilentz, R. E., & Kern, S. E. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65054-7 · Cited by 373 · cited 2×
“90% of human PDAs, occur in the earliest steps of tumor progression (24), followed by alterations in tumor-suppressor genes, including TP53, SMAD4, and CDKN2A (25).”
BackgroundInfluentialRutkowski, M. R., Stephen, T. L., Svoronos, N., Allegrezza, M. J., Tesone, A. J., Perales-Puchalt, A., Brencicova, E., Escovar-Fadul, X., Nguyen, J. M., Cadungog, M. G., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.009 · Cited by 311 · cited 1×
“In parallel, we found that deletion of the Gal1 gene induces up-regulation of CD4 and CD8 T cell tumor infiltrates as shown in other tumor types, including melanoma (90), Hodgkin lymphoma (91), neuroblastoma (92), lung adenocarcinoma (93), ovary carcinoma (94), and breast adenocarcinoma (95).”
BackgroundSelf-citationJones, D. T., Trowbridge, I. S., & Harris, A. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3857 · Cited by 75 · cited 1×
“In addition, our microarray data suggest that Gal1 can also promote angiogenesis in PDA through an indirect mechanism mediated by the up-regulation of IL-1α, which might induce secretion of proangiogenic cytokines (80), or by the down-regulation of the transferrin receptor (TFRC), which may promote hypoxia and augment…”
BackgroundKoide, T., Hayata, T., & Cho, K. W. Y. (2006) · Development · doi:10.1242/dev.02393 · Cited by 69
Cited by
The Extracellular Matrix and Pancreatic Cancer: A Complex Relationship
Weniger, M., Honselmann, K., & Liss, A. (2018) · Cancers · doi:10.3390/cancers10090316 · Cited by 268
Perez, V. M., Kearney, J. F., & Yeh, J. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.751311 · Cited by 143
The protein inputs of an ultra-predictive aging clock represent viable anti-aging drug targets
Johnson, A. A., Shokhirev, M. N., & Lehallier, B. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101404 · Cited by 22
Metadata
- Authors
- Orozco, C. A., Martinez-Bosch, N., Guerrero, P. E., Vinaixa, J., Dalotto-Moreno, T., Iglesias, M., Moreno, M., Djurec, M., Poirier, F., Gabius, H.-J., Fernandez-Zapico, M. E., Hwang, R. F., Guerra, C., Rabinovich, G. A., & Navarro, P.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2018-04-04
- Volume
- 115
- Issue
- 16
- Pages
- E3769-E3778
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2796269683
- Cited by
- 158
- References
- 22
- FWCI
- 6.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.